Exenatide started in lizard saliva. It is a synthetic copy of exendin-4, a 39-amino-acid peptide that endocrinologist John Eng isolated from the venomous saliva of the Gila monster (Heloderma suspectum) while studying its biochemistry. That origin is not marketing color. The peptide shares roughly 50% of its sequence with human glucagon-like peptide-1 (GLP-1), and the parts that differ are what made it useful as a drug (National Institute on Aging).
It is also one of the few peptides on this site that is a fully approved medicine, not a research-only compound. Exenatide is sold as Byetta (twice-daily) and Bydureon (once-weekly extended release), and the catalog name you'll see is exendin-4. CAS 141758-74-9.
What it is and how it works
Exenatide is a GLP-1 receptor agonist in the incretin-mimetic class. Native GLP-1 is a gut hormone released after a meal; it tells the pancreas to release insulin, but only when blood glucose is elevated. That glucose-dependence is the point, because it limits the risk of driving sugar too low. Exenatide binds the same pancreatic GLP-1 receptor and does the same job: it boosts glucose-dependent insulin secretion, suppresses inappropriately high glucagon, and slows gastric emptying (FDA Byetta label).
The reason a lizard peptide works as a drug and native GLP-1 doesn't is durability. Human GLP-1 is chopped up by the enzyme DPP-4 within about two minutes. Exendin-4 resists DPP-4, so it lasts far longer in the bloodstream (NIA).
The clinical record
Byetta was approved by the FDA on April 28, 2005, the first incretin mimetic ever cleared, on the strength of the three 30-week phase 3 "AMIGO" trials in patients with type 2 diabetes. The once-weekly Bydureon formulation followed in 2012.
The biggest trial is EXSCEL. It randomized 14,752 people with type 2 diabetes to once-weekly exenatide (2 mg) or placebo and tracked major cardiovascular events. The result was neutral: exenatide was non-inferior to placebo for safety but did not significantly reduce cardiovascular death, heart attack, or stroke (11.4% vs 12.2%, P=0.06 for superiority). So it is safe for the heart, but unlike some newer drugs in the class it did not show a clear cardiovascular benefit (NEJM 2017).
Exenatide has also been tested well outside diabetes. Because GLP-1 receptors sit on neurons and the peptide is neuroprotective in animal models, it was a leading candidate to slow Parkinson's disease. The phase 3 Exenatide-PD3 trial put that to a hard test: 194 participants, 96 weeks, once-weekly exenatide vs placebo. It found no benefit. Movement symptoms worsened at the same rate as placebo, and brain imaging showed no difference (The Lancet, 202402808-3/fulltext)). It was the largest and longest GLP-1 trial in Parkinson's to date, and the negative result matters as much as a positive one would have.
Regulatory and WADA status
Exenatide is an approved prescription drug for type 2 diabetes in the US and many other markets. The exendin-4 sold as a "research chemical" peptide is the same molecule but is not a regulated medicine in that form, and is labeled research-use-only, not for human consumption.
On anti-doping: GLP-1 receptor agonists are not currently prohibited by WADA. They sit on WADA's Monitoring Program, which means the agency is watching their use in athletes but does not ban them and does not require a Therapeutic Use Exemption at this time. That status can change (USADA).
The quality angle for buyers
For a peptide bought outside a pharmacy, identity and purity are the whole game. A vial labeled exendin-4 should be backed by a recent third-party Certificate of Analysis showing what the material actually is: mass spec or HPLC confirming the 39-residue sequence and the stated purity (vendors typically advertise tiers like 98% or greater than 99%), plus reconstitution and storage details. Independent COAs and the vendor ratings this site aggregates exist to check that the label matches the contents. None of that turns a research peptide into an approved therapy, and nothing here is medical or dosing advice.